Xaira Therapeutics
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.0Battributed |
|---|---|
| Latest round | series-a, $1.0B, 2024-04-01attributed |
| Founded | 2024 |
| Headquarters | San Francisco, USA |
| Industry | bio |
| Stage | series-a |
| Website | xaira.com |
Xaira Therapeutics combines generative AI drug discovery with wet-lab biology to design novel small molecules and biologics. The company targets oncology, immunology, and rare-disease indications across multiple modalities. Founders span Stanford's protein-design group, ARCH Venture Partners, and Foresite Labs.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | series-a | $1.0B | undisclosed |
Detected tech stack
Cloudflare, jsDelivr, cdnjs, OneTrust, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $1.0B | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $1.0B | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | xaira.com, read 2026-04-29 |
| Description | self-reported | xaira.com, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.